Global Research on Allergic Rhinitis Drugs Market to 2020: Analysis and Forecasts Report

1. Global Allergic Rhinitis Drugs Market 2016-2020- Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with Allergic Rhinitis Drugs Market in subject line and your contact details. Read 90 Pages Report at http://www.reportsnreports.com/reports/477144-global-allergic- rhinitis-drugs-market-2016-2020.html . Allergic rhinitis is caused by the interaction of airborne allergens with specific immunoglobulin E (IgE) type antibodies on the surface of mast cells. This interaction causes mast cells to release and synthesize chemicals, causing inflammation of the surrounding tissues. Typical symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion. Extranasal symptoms such as allergic conjunctivitis, itchy ears and palate, and asthma may also occur. Allergic rhinitis is treated using medications such as antihistamines, intranasal corticosteroids, or immunotherapies. Alternative forms of treatment are also employed in certain cases. The analysts forecast global allergic rhinitis market to grow at a CAGR of 0.95% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global allergic rhinitis drugs market for the period 2016-2020. To calculate the market size, it considers revenue generated from the sales of prescription and off-label drugs used to treat allergic rhinitis. The market is divided into the following segments based on geography: Americas APAC Europe The report, Global Allergic Rhinitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Buy a copy of report @ http://www.reportsnreports.com/Purchase.aspx?name=477144 for US $2500. Key vendors AstraZeneca Global Allergic Rhinitis Drugs Market 2016-2020

2. GlaxoSmithKline Meda Pharmaceuticals Merck Sanofi UCB Other prominent vendors Adamis Pharmaceuticals Alcon Alergo Pharma ALK-Abelló Allergy Therapeutics Almirall Ampio Anergis Apotex Ares Life Sciences Array BioPharma Aspen Pharmacare Atopix Therapeutics Barr Laboratories Belcher Pharmaceuticals Circassia Pharmaceuticals Dainippon Sumitomo DBV Technologies Dr Reddy's Laboratories Eddingpharm Genentech Greer Laboratories Hanmi Pharmaceuticals Hisamitsu Pharmaceutical Intas Pharmaceuticals Kyowa Hakko Lupin Pharmaceuticals Mitsubishi Tanabe Pharma Mylan Nektar Therapeutics Novartis Nuvo Research Nycomed Omega Pharma Ono Pharmaceuticals Global Allergic Rhinitis Drugs Market 2016-2020

3. Pfizer Revance Therapeutics Roxane Laboratories (Boehringer Ingelheim) Shionogi Stallergenes Sun Pharmaceuticals Takeda Pharmaceutical Teva Pharmaceuticals Verona Pharma VentiRx Pharmaceuticals Market driver Increased prevalence of allergic rhinitis Market challenge Patent expiries and competition from generic drugs Market trend Increased R&D Inquire before Buying at http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=477144 . Key questions answered in this report 1.What will the market size be in 2020 and what will the growth rate be? 2.What are the key market trends? 3.What is driving this market? 4.What are the challenges to market growth? 5.Who are the key vendors in this market space? 6.What are the market opportunities and threats faced by the key vendors? 7.What are the strengths and weaknesses of the key vendors? List of Exhibits Exhibit 01: Product offerings Exhibit 02: Types of allergic rhinitis Exhibit 03: Risk factors associated with allergic rhinitis Global Allergic Rhinitis Drugs Market 2016-2020

4. Exhibit 04: Major diagnostic procedures for allergic rhinitis Exhibit 05: Imaging studies used to diagnose and evaluate allergic rhinitis Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis Exhibit 07: Non-pharmacological therapies for allergic rhinitis Exhibit 08: Examples of non-pharmacological therapies Exhibit 09: Treatment algorithm of allergic rhinitis Exhibit 10: Prevalence of allergic rhinitis in China Exhibit 11: Global allergic rhinitis drugs market: Pipeline portfolio Exhibit 12: Allergic rhinitis clinical trials by development phase 2015 Exhibit 13: Allergic rhinitis clinical trials by trial status 2015 Exhibit 14: Global allergic rhinitis drugs market 2015-2020 ($ billions) Exhibit 15: Five forces analysis Exhibit 16: Global allergic rhinitis market based on class of drugs Exhibit 17: Examples of prescription and OTC intranasal corticosteroids Exhibit 18: Global allergic rhinitis drugs market based on class of drugs 2015 Exhibit 19: Global allergic rhinitis drugs market based on class of drugs 2015-2020 ($ billions) Exhibit 20: Global antihistamines drugs market 2015-2020 ($ billions) Exhibit 21: Global intranasal corticosteroids drugs market 2015-2020 ($ billions) Exhibit 22: Global immunotherapies drugs market 2015-2020 ($ billions) Exhibit 23: Global allergic rhinitis drugs market by route of administration Exhibit 24: Global allergic rhinitis drugs market segmentation by dosage form Exhibit 25: Global allergic rhinitis drugs market by geography 2015 Global Allergic Rhinitis Drugs Market 2016-2020

5. Exhibit 26: Global allergic rhinitis drugs market revenue by geography 2015-2020 ($ billions) Exhibit 27: Allergic rhinitis drugs market in Americas 2015-2020 ($ billions) Exhibit 28: Allergic rhinitis drugs market in EMEA 2015-2020 ($ billions) Exhibit 29: Allergic rhinitis drugs market in APAC 2015-2020 ($ millions) Exhibit 30: Drivers of global allergic rhinitis drugs market Exhibit 31: Impact of drivers Exhibit 32: Challenges of global allergic rhinitis drugs market Exhibit 33: Impact of drivers and challenges Exhibit 34: Trends of global allergic rhinitis drugs market Exhibit 35: Drugs that underwent Rx-to-OTC switch in the US Exhibit 36: Global allergic rhinitis drugs market vendor share analysis 2015 Exhibit 37: YoY revenue comparison of top drugs for allergic rhinitis 2012-2014 ($ billions) Exhibit 38: AstraZeneca: Business segmentation by revenue 2014 Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014 Exhibit 41: AstraZeneca: Key takeaways Exhibit 42: GlaxoSmithKline: Business segmentation by revenue 2014 Exhibit 43: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 44: GlaxoSmithKline: Geographical segmentation by revenue 2014 Exhibit 45: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions) Exhibit 46: GlaxoSmithKline: Key takeaways Exhibit 47: Meda Pharmaceuticals: Product segmentation by revenue 2014 Global Allergic Rhinitis Drugs Market 2016-2020

6. Exhibit 48: Meda Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions) Exhibit 49: Meda Pharmaceuticals: Geographical segmentation by revenue 2014 Exhibit 50: Meda Pharmaceuticals: Top-selling drugs Exhibit 51: Meda Pharmaceuticals: YoY growth and revenue of Dymista 2012-2014 ($ millions) Exhibit 52: Meda Pharmaceuticals: YoY growth and revenue of EpiPen 2012-2014 ($ millions) Exhibit 53: Meda Pharmaceuticals: Key takeaways Exhibit 54: Merck: Business segmentation by revenue 2014 Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 56: Merck: Geographical segmentation by revenue 2014 Exhibit 57: Merck: Top-selling drugs Exhibit 58: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions) Exhibit 59: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions) Exhibit 60: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions) Exhibit 61: Merck: Key takeaways Exhibit 62: Sanofi: Business segmentation by revenue 2014 Exhibit 63: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 64: Sanofi: Geographical segmentation by revenue 2014 Exhibit 65: Sanofi: Top-selling drugs Exhibit 66: Sanofi: YoY growth and revenue of Allegra 2012-2014 ($ millions) Exhibit 67: Sanofi: YoY growth and revenue of Allegra OTC 2012-2014 ($ millions) Exhibit 68: Sanofi: YoY revenue comparison of Nasacort ($ millions) Exhibit 69: Sanofi: Key takeaways Global Allergic Rhinitis Drugs Market 2016-2020

7. Exhibit 70: UCB: Product segmentation by revenue 2014 Exhibit 71: UCB: Product segmentation by revenue 2013 and 2014 ($ billions) Exhibit 72: UCB: Geographical segmentation by revenue 2014 Exhibit 73: UCB: YoY growth and revenue of Zyrtec 2012-2014 ($ millions) Exhibit 74: UCB: YoY growth and revenue of Xyzal 2012-2014 ($ millions) Exhibit 75: UCB: Key takeaways Browse All Reports on Pharmaceuticals About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. Global Allergic Rhinitis Drugs Market 2016-2020